Insider Selling: Bioventus Inc. (NYSE:BVS) SVP Sells 2,535 Shares of Stock

Bioventus Inc. (NYSE:BVS - Get Free Report) SVP Katrina J. Church sold 2,535 shares of the firm's stock in a transaction dated Monday, December 23rd. The stock was sold at an average price of $10.53, for a total value of $26,693.55. Following the completion of the transaction, the senior vice president now owns 47,264 shares of the company's stock, valued at approximately $497,689.92. The trade was a 5.09 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Bioventus Stock Performance

BVS traded up $0.32 on Thursday, reaching $11.00. The stock had a trading volume of 255,781 shares, compared to its average volume of 391,340. The business's 50-day moving average price is $11.86 and its two-hundred day moving average price is $9.77. The company has a market cap of $892.71 million, a P/E ratio of -18.03 and a beta of 0.79. Bioventus Inc. has a 12-month low of $3.90 and a 12-month high of $14.38. The company has a current ratio of 1.41, a quick ratio of 0.99 and a debt-to-equity ratio of 1.85.

Bioventus (NYSE:BVS - Get Free Report) last announced its quarterly earnings results on Tuesday, November 5th. The company reported $0.06 earnings per share for the quarter, meeting the consensus estimate of $0.06. The firm had revenue of $138.96 million during the quarter, compared to analyst estimates of $132.57 million. Bioventus had a positive return on equity of 15.61% and a negative net margin of 7.11%. During the same quarter in the previous year, the business earned $0.05 EPS. Sell-side analysts forecast that Bioventus Inc. will post 0.41 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on the stock. JPMorgan Chase & Co. upgraded shares of Bioventus from an "underweight" rating to a "neutral" rating and increased their price objective for the stock from $12.00 to $13.00 in a research note on Tuesday, December 17th. Canaccord Genuity Group upped their target price on Bioventus from $12.00 to $15.00 and gave the stock a "buy" rating in a research note on Wednesday, November 6th. Finally, Craig Hallum lifted their price target on Bioventus from $12.00 to $17.00 and gave the company a "buy" rating in a research report on Friday, September 27th.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in BVS. Virtus Fund Advisers LLC acquired a new position in shares of Bioventus during the 3rd quarter worth about $42,000. Quest Partners LLC acquired a new position in shares of Bioventus during the third quarter valued at approximately $51,000. Quarry LP purchased a new position in shares of Bioventus in the third quarter valued at approximately $59,000. HB Wealth Management LLC acquired a new stake in shares of Bioventus in the second quarter worth approximately $60,000. Finally, Covestor Ltd acquired a new position in Bioventus in the 3rd quarter valued at $69,000. 62.94% of the stock is owned by institutional investors and hedge funds.

About Bioventus

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.